CD38 drugs for Multiple Myeloma
12 tracked CD38 drugs in the Multiple Myeloma race. The class explanation lives on the CD38 page; the full indication pipeline across every mechanism is on the Multiple Myeloma page.
2 approved / phase 48 Phase 31 Phase 1/21 Phase 1
Head-to-head evidence: BCD-264 vs CID-103 · BCD-264 vs Daratumumab · BCD-264 vs Felzartamab · BCD-264 vs Isatuximab · BCD-264 vs Lumrotatug · CID-103 vs CT-P44